Introduction {#Sec1}
============

Refractive astigmatism results from the optical summation of the eye's corneal astigmatism and astigmatism from internal eye components (e.g. lens). In most individuals, these two sources of astigmatism tend to compensate for each other, such that overall refractive astigmatism is typically low in magnitude (Kelly et al. [@CR42]). High levels of refractive astigmatism are usually the result of high corneal astigmatism rather than high internal astigmatism (Keller et al. [@CR41]; Kee [@CR38]). Astigmatism in infancy is a risk factor for amblyopia (Abrahamsson and Sjostrand [@CR1]). In later life, astigmatism commonly accompanies myopia and hyperopia (Mandel et al. [@CR55]; Kee et al. [@CR40]; Farbrother et al. [@CR20]), reducing visual acuity unless corrected by spectacles, contact lenses or refractive surgery (Read et al. [@CR72]).

The results of twin (Dirani et al. [@CR15]; Grjibovski et al. [@CR25]; Parssinen et al. [@CR65]; Teikari and O'Donnell [@CR82]), family (Rakhshani et al. [@CR71]; Mash et al. [@CR56]) and molecular genetic studies (Fan et al. [@CR19]; Lopes et al. [@CR51]; Mackey et al. [@CR54]) suggest that astigmatism is highly heritable, as does its high prevalence in specific ethnic groups such as Native Americans (McKean-Cowdin et al. [@CR57]; Mohindra and Nagaraj [@CR60]; Harvey et al. [@CR31]). For refractive astigmatism, the heritability has been estimated at 0.33 to 0.63 from twin studies (Hammond et al. [@CR29]; Grjibovski et al. [@CR25]; Parssinen et al. [@CR66]). Using a case--control genome-wide association study (GWAS) meta-analysis of 8,513 individuals of Asian ethnicity, Fan et al. ([@CR19]) identified the *PDGFRA* gene on chromosome 4q12 as a susceptibility locus for corneal astigmatism. Cases were defined as subjects with corneal astigmatism (averaged between the two eyes) of at least 0.75 diopters (D) and controls as those with corneal astigmatism less than 0.75 D. Three single nucleotide polymorphisms (SNPs) attained genome-wide significance (*P* \< 5.0E−08); rs7677751, rs2307049 and rs7660560. SNPs in the same region of *PDGFRA* have since been found to be associated with both corneal curvature and axial length (Han et al. [@CR30]; Guggenheim et al. [@CR27]; Mishra et al. [@CR58]), but not with spherical refractive error (Guggenheim et al. [@CR27]). A second GWAS meta-analysis in 22,100 individuals of European descent by Lopes et al. ([@CR51]) reported suggestive evidence that SNPs in the *VAX2* gene on chromosome 2p13 also confer susceptibility to refractive astigmatism (most strongly associated SNP, rs3771395; *P* = 2.0E−07). These authors modelled astigmatism as a continuous trait, using an inverse normal transformation of the refractive astigmatism averaged between the two eyes.

The GWAS meta-analyses of Fan et al. ([@CR19]) and Lopes et al. ([@CR51]) both assessed large numbers of individuals derived from cohorts that were largely population based. It is therefore unlikely that common autosomal genetic variants, i.e. those with a minor allele frequency (MAF) \>5 %, with profound effects on the risk of developing astigmatism (e.g. OR \> 2) exist, as both studies would have had high power to detect them. Instead, the results of the two studies imply that most of the additive genetic risk for astigmatism arises from the combined action of a large number of individual risk variants, each with a small effect. This scenario, which also holds for spherical refractive error (Solouki et al. [@CR76]; Hysi et al. [@CR35]; Verhoeven et al. [@CR84]; Kiefer et al. [@CR44]), suggests that substantially increasing the sample size of GWAS meta-analyses will be an effective method of discovering new variants, albeit with increasingly diminishing returns (Lango Allen et al. [@CR48]). Here, we describe the largest GWAS for refractive astigmatism yet undertaken involving almost 46,000 persons.

Methods {#Sec2}
=======

Selection of studies for inclusion in the meta-analysis {#Sec3}
-------------------------------------------------------

The CREAM consortium comprises researchers from more than 30 research groups who share a common interest in the genetics of refractive error. From March to July 2012, all Principal Investigators (PIs) of studies known to CREAM members who had collected refractive error phenotype information and genome-wide genotyping information on a study sample were invited to join CREAM. An analysis plan detailing the protocol for the astigmatism GWAS meta-analysis was circulated, inviting all PIs to perform the requested analyses and to submit GWAS results for their study sample. There were no restrictions on which studies were eligible to join the meta-analysis.

Study cohorts and meta-analysis overview {#Sec4}
----------------------------------------

GWAS results were meta-analysed for a total of 32 cohorts. The subject demographics of the cohorts are summarised in Table [1](#Tab1){ref-type="table"}: Further details can be found in the Supplement and the previous publications (Rahi et al. [@CR69]; Fraser et al. [@CR23]; Boyd et al. [@CR6]; Vitart et al. [@CR86]; Parssinen et al. [@CR64]; Sperduto et al. [@CR78]; Foong et al. [@CR21]; Foran et al. [@CR22]; Cornes et al. [@CR14]; Hofman et al. [@CR32]; Burdon et al. [@CR7]; Khor et al. [@CR43]; Oexle et al. [@CR62]; Vithana et al. [@CR87]; Paterson et al. [@CR67]; Klein et al. [@CR47]; Mackey et al. [@CR53]; Nelis et al. [@CR61]; Raitakari et al. [@CR70]; Spector and Williams [@CR77]; Wichmann et al. [@CR91]; Pardo et al. [@CR63]; Aulchenko et al. [@CR3]; Clemons et al. [@CR13]; Kassoff et al. [@CR36], [@CR37]; Mitchell et al. [@CR59]; Shamoon et al. [@CR75]). The mean age of the participants in each cohort varied from 15 to 74 years and 37,608 of them were of White European ancestry while 10,212 were of Asian ancestry. Because the magnitude and axis of astigmatism are known to vary with age (Anstice [@CR2]; Lyle [@CR52]), and to limit the effects of differing SNP-causal variant relationships across ethnicities, meta-analyses were carried out separately for (a) White Europeans aged \<25 years, (b) White Europeans aged ≥25 years, and (c) Asians aged ≥25 years. This age classification scheme follows that adopted previously by the CREAM consortium (Verhoeven et al. [@CR83], [@CR84]), and was agreed to by the CREAM Executive Committee prior to commencement of the meta-analyses. A final meta-analysis was performed combining all independent samples from these three groups with the SCORM study of Asians aged \<25 years. Each participating study defined the astigmatism trait in the same manner and performed association analyses specifically for this study using equivalent logistic regression models (described below and in the supplement).Table 1Cohort demographicsStudyEthnicity*N* (cases/controls)Age, years (mean ± SD)Astigmatism, D (mean ± SD)Astigmatism median, D (IQR)Astigmatism, D (range)% FemaleEuropean adult cohorts 1958 British Birth CohortWhite European1,645 (182/1,463)42 ± 00.47 ± 0.530.38 (0.13--0.63)0.00--4.5045.8 ALSPAC mothersWhite European1,889 (343/1,546)44 ± 20.63 ± 0.530.50 (0.25--0.75)0.00--4.62100.0 AREDSWhite European1,864 (567/1,297)68 ± 50.77 ± 0.670.75 (0.25--1.00)0.00--4.5059.2 BATSplusTESTWhite European204 (49/155)40 ± 140.63 ± 0.570.38 (0.25--0.89)0.00--2.7562.7 CROATIA-KorculaWhite European826 (135/691)56 ± 130.63 ± 0.520.50 (0.25--0.75)0.00--4.0064.7 CROATIA-SplitWhite European343 (35/308)51 ± 130.55 ± 0.410.44 (0.25--0.63)0.00--3.0056.3 CROATIA-VisWhite European529 (104/425)56 ± 130.68 ± 0.570.51 (0.21--0.81)0.00--4.6859.7 ERF4White European2,485 (472/2,013)49 ± 140.58 ± 0.540.50 (0.25--0.75)0.00--4.1343.4 FITSAWhite European87 (18/69)68 ± 30.75 ± 0.520.63 (0.38--0.88)0.00--3.50100.0 FraminghamWhite European1,532 (745/787)60 ± 120.78 ± 0.560.63 (0.38--1.00)0.00--4.3856.1 GUTENBERGWhite European3,954 (640/3,314)56 ± 110.55 ± 0.540.44 (0.13--0.75)0.00--4.6349.2 KORAWhite European1,852 (448/1,404)56 ± 120.72 ± 0.640.50 (0.25--1.00)0.00--4.7550.6 OGLIASTRAWhite European472 (49/423)52 ± 160.31 ± 0.520.00 (0.00--0.50)0.00--3.0069.0 ORCADESWhite European502 (113/389)58 ± 140.70 ± 0.650.56 (0.22--0.90)0.00--4.6956.8 ROTTERDAM 1White European5,422 (2,193/3,229)69 ± 90.95 ± 0.660.75 (0.38--1.13)0.00--4.7558.6 ROTTERDAM 2White European1,973 (725/1,248)64 ± 70.89 ± 0.590.75 (0.44--1.07)0.00--4.5054.3 ROTTERDAM 3White European1,971 (580/1,391)56 ± 60.81 ± 0.570.63 (0.31--0.94)0.00--4.0056.5 TwinsUKWhite European2,658 (751/1,907)55 ± 130.80 ± 0.650.63 (0.38--1.00)0.00--4.8891.1 WESDR adultsWhite European280 (69/211)35 ± 80.71 ± 0.650.50 (0.19--0.81)0.00--4.5075.4 YFSWhite European1,480 (269/1,211)42 ± 50.64 ± 0.520.50 (0.25--0.75)0.00--4.1355.3Asian adult cohorts BESChinese585 (154/431)62 ± 90.66 ± 0.590.50 (0.25--1.00)0.00--3.5065.8 HK-MGS adultsChinese120 (59/61)34 ± 71.29 ± 1.050.97 (0.50--1.84)0.00--5.3161.7 SCESChinese1,662 (670/992)57 ± 90.99 ± 0.630.85 (0.48--1.23)0.00--4.3048.8 SIMESMalay2,165 (706/1,459)57 ± 110.90 ± 0.660.73 (0.39--1.06)0.00--4.8550.8 SINDIIndian1,998 (739/1,259)56 ± 90.96 ± 0.620.83 (0.47--1.18)0.00--4.5348.7 SP2Chinese1,954 (543/1,411)48 ± 110.81 ± 0.560.68 (0.36--0.99)0.00--4.1854.2 STARSChinese811 (205/606)39 ± 50.72 ± 0.670.60 (0.21--0.94)0.00--4.3248.0European youngsters cohorts ALSPAC childrenWhite European3,828 (580/3,248)15 ± 0.30.65 ± 0.420.63 (0.38--0.75)0.00--4.2548.8 BATSplusTEST childrenWhite European561 (60/501)18 ± 40.40 ± 0.480.25 (0.13--0.5)0.00--4.0054.0 RAINEWhite European1,007 (215/792)20 ± 00.74 ± 0.400.69 (0.45-0.93)0.08--3.1149.3 WESDR childrenWhite European244 (52/192)18 ± 40.64 ± 0.570.50 (0.25--0.75)0.00--3.38)50.8Asian youngsters cohort SCORMChinese917 (247/670)11 ± 10.77 ± 0.660.57 (0.21--0.94)0.00--4.3248.0

Phenotypic assessment {#Sec5}
---------------------

Subjects underwent an ophthalmic examination that included either subjective refraction, cycloplegic autorefraction or non-cycloplegic autorefraction (Supplemental Methods and Supplemental Table S1a). Astigmatism was defined in the same way during association analysis in all cohorts participating in this meta-analysis study. Participants with conditions that could alter refraction, such as cataract surgery, laser refractive procedures, retinal detachment surgery, keratoconus or ocular or systemic syndromes were excluded. Additional exclusion criteria were, firstly, a cylinder power ≥5.00 D in either eye (to exclude subjects with undiagnosed keratoconus or potential measurement errors), and secondly, a difference in cylinder power between the two eyes beyond four standard deviations from the mean (except for subjects with data for only one eye). Subjects were classified as astigmatic cases if the average cylinder power in the two eyes was ≥1.00 D and as controls otherwise (note that cylinder axis was ignored). The threshold value of 1.00 D was chosen due to its common usage in prior work (Read et al. [@CR72]; Huynh et al. [@CR34]). The average of the two eyes was taken to maximise statistical power (Carbonaro et al. [@CR9]).

Genotyping and genotype imputation {#Sec6}
----------------------------------

Genotyping and imputation were carried out as described previously (Verhoeven et al. [@CR84]). In brief, participants in each cohort were genotyped using a whole genome SNP platform. The genotypes of subjects that passed a series of quality control (QC) filters, including call rate at least \>95 % and ancestry matching that of the reference population, were imputed to a common set of markers (HapMap Phase 2) with either MACH (Li et al. [@CR49]) or IMPUTE (Howie et al. [@CR33]). SNPs that passed cohort-specific QC metrics were used as a framework for imputation, and reference haplotypes were chosen from the best available HapMap Phase 2 ancestry group (Verhoeven et al. [@CR84]). See Supplemental Methods and Table S1b for more details.

Statistical analysis {#Sec7}
--------------------

A GWAS was carried out separately for each participant cohort. SNPs were tested individually for association with astigmatism in a logistic regression model, with case/control status as the dependent variable. SNP imputed dosage was modelled as a linear covariate (on a continuous scale from 0 to 2) where one allele was assigned as the reference allele and the other allele the risk allele. Age and sex were included as additional covariates when appropriate. If significant population stratification was detected in a cohort, then either the first two principal components (PCs) were included in the logistic regression or an analysis method was used that jointly adjusted for population stratification and cryptic relatedness as part of the analysis. This approach is commonly used in GWAS meta-analysis (Eeles et al. [@CR17]; Chen et al. [@CR11]; Wang et al. [@CR89]). Details of the GWAS analyses performed in each cohort are given in Supplemental Methods. SNPs were carried forward for meta-analysis if they met the following criteria of a MAF \>1 %, and an OR (odds ratio) between 0.2 and 5.0 (the latter step being included to remove SNPs with an OR of approximately zero or infinity, which occurred for a few SNPs in the smaller cohorts due to low minor allele counts). Effect estimates were reported with reference to the positive strand of the NCBI Build 36 reference sequence of the human genome. Meta-analysis was carried out using a fixed effects model with METAL (Willer et al. [@CR92]). For the meta-analysis of all cohorts, the adult ALSPAC sample was excluded because, given the inclusion of the ALSPAC young persons sample (biological relatives of the adults), this could have led to falsely inflated estimates of association. The number of subjects contributing information to the meta-analysis summary statistic varied, as shown in Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}. This occurred primarily through markers being monomorphic (uninformative) in certain samples, and to a small extent through missing data for certain markers in specific individuals. A *P* value \<5.0E−08 was used to declare genome-wide significance (Dudbridge and Gusnanto [@CR16]; Evangelou and Ioannidis [@CR18]).Table 2Most strongly associated SNPs in the 3 meta-analysesSNPChrPosRANRARAF (min--max)OR95 % CI*P* value*I* ^2^*N*Gene(s)European subjects aged ≥25 years rs1401327249900987AG0.113--0.1741.1571.098--1.2183.92E−08031,694*NRXN1* rs17795388249900356GA0.113--0.1741.1571.098--1.2184.16E−08031,691*NRXN1* rs11690625249908115CA0.113--0.1751.1561.098--1.2184.17E−08031,731*NRXN1* rs17795358249897928AG0.113--0.1731.1561.097--1.2184.94E−08031,672*NRXN1* rs925931249913312CT0.113--0.1731.1481.090--1.2102.06E−07031,727*NRXN1* rs885560249909442GA0.113--0.1751.1461.088--1.2072.46E−07031,728*NRXN1* rs6708111249878453AC0.102--0.1681.1391.082--1.2007.27E−07031,531*NRXN1* rs11690252249890187TG0.230--0.3421.1051.060--1.1512.59E−06031,511*NRXN1* rs1878856249877706CT0.214--0.3361.1051.059--1.1533.56E−06031,603*NRXN1* rs1263807531.42E + 08CT0.014--0.0241.3761.200--1.5774.69E−06027,304*TRIM42/CLSTN2* rs2309717427859336AC0.089--0.1701.1431.083--1.2061.02E−0611.831,143*STIM2/PCDH7* rs2871434429931147TA0.095--0.1541.1401.079--1.2042.66E−0613.631,664*STIM2/PCDH7* rs12212674622195053AT0.496--0.6211.0991.058--1.1421.45E−06031,691*LINC00340* rs6901423622194271GA0.496--0.6211.0991.057--1.1421.63E−06031,689*LINC00340* rs4712652622186594AG0.495--0.6871.0971.055--1.1413.13E−06028,910*LINC00340* rs9366427622204592GC0.487--0.6191.0941.053--1.1364.15E−06031,773*LINC00340* rs47999641826239477GT0.020--0.0481.2671.152--1.3941.16E−06031,881*MIR302F* rs126072431826229228GA0.020--0.0501.2641.149--1.3921.60E−06031,882*MIR302F*European subjects aged \<25 years rs66886131165218493TC0.240--0.2531.3091.170--1.4652.68E−0605,640*MAEL* rs13278661165219534GA0.238--0.2531.3081.169--1.4642.89E−0605,640*MAEL* rs75506981165217705CT0.240--0.2531.3081.168--1.4633.02E−0605,640*MAEL* rs75288491165221494GA0.240--0.2531.3071.168--1.4633.11E−0605,640*MAEL* rs75181551165221520GT0.240--0.2531.3071.168--1.4623.19E−0605,640*MAEL* rs75459111165214305AG0.240--0.2531.3091.169--1.4673.35E−0605,640*MAEL* rs66820621165216603CG0.240--0.2531.3091.168--1.4673.39E−0605,640*MAEL* rs22968371165225225CT0.240--0.2531.3051.166--1.4613.53E−0605,640*MAEL* rs115783361165225334GT0.240--0.2531.3041.166--1.4603.71E−0605,640*MAEL* rs13662005115349718GT0.312--0.3211.3081.174--1.4571.04E−0648.75,640*AQPEP* rs17712049748236741CT0.875--0.9041.5691.295--1.9024.39E−0605,640*ABCA13* rs13257518832755116AT0.177--0.2171.3701.202--1.5612.36E−0615.75,640*NRG1* rs10503929832733525CT0.167--0.2151.3521.192--1.5342.68E−0632.35,640*NRG1* rs2975500832724907AG0.110--0.1611.4351.231--1.6733.95E−0605,640*NRG1*Asian adults rs75348241101394034AG0.967--0.9742.3041.651--3.2149.00E−0704,812*LOC101928334* rs10496034254998439CG0.170--0.2871.2161.122--1.3182.13E−0608,780*EML6* rs4284452054469954TG0.713--0.9541.3141.175--1.4701.84E−0608,908*CASS4/GCNT7* rs69992054527308AG0.713--0.9571.3031.164--1.4594.30E−0608,904*CASS4/GCNT7*The table shows all SNPs with *P* \< 5.0E−06*RA* risk allele, *NRA* non--risk (reference) allele, *RAF* risk allele frequency in each cohort, *OR* odds ratio, *95* *%* *CI* 95 % confidence interval of odds ratio, *I* ^*2*^ heterogeneity statistic, *N* total sample sizeTable 3Most strongly associated SNPs in the meta--analysis of all cohortsSNPChrPosRANRARAF (min--max)OR95 % CI*P* value*I* ^2^*N*Geners1401327249900987AG0.113--0.1741.1391.084--1.1982.93E−07035,445NRXN1rs11690625249908115CA0.113--0.1751.1391.084--1.1972.95E−07035,482NRXN1rs17795388249900356GA0.113-0.1741.1391.084--1.1983.10E−07035,442NRXN1rs17795358249897928AG0.113--0.1731.1391.083--1.1973.67E−07035,423NRXN1rs925931249913312CT0.010--0.1731.1251.071--1.1822.64E−063.339,567NRXN1rs885560249909442GA0.010--0.1751.1231.069--1.1793.46E−065.539,566NRXN1rs6708111249878453AC0.102--0.1681.1241.069--1.1824.42E−06035,282NRXN1rs758164128543557TC0.012--0.1031.2251.123--1.3364.74E−06041,865NRXN1rs6892230565175520AG0.016--0.0781.2361.133--1.3491.87E−0641.337,591NLNrs12212674622195053AT0.134--0.6211.0861.050--1.1231.49E−06045,134LINC00340rs6901423622194271GA0.134--0.6211.0831.048--1.1203.00E−06045,132LINC00340rs1034071622205354CT0.137--0.6081.0811.046--1.1183.73E−06045,330LINC00340rs7823467860241288TC0.388--0.7131.0851.052--1.1203.47E−0722.945,273TOXrs10086929860252851AG0.430--0.7091.0831.049--1.1187.36E−0722.345,156TOXrs6471768860230697TA0.435--0.7101.0821.048--1.1171.07E−0623.945,125TOXrs4531042860251242GA0.388--0.7371.0821.048--1.1181.45E−0632.945,277TOXrs4738757860218783AG0.388--0.7011.0801.046--1.1151.89E−0626.945,122TOXrs12675886860309643CT0.458--0.7041.0791.045--1.1142.50E−0614.345,082TOXrs6997378860330443TG0.460--0.7051.0771.043--1.1114.95E−0617.345,085TOXrs194414611130195372AG0.524--0.6081.0801.046--1.1152.62E−0617.345,243LOC100507431rs793498511130194532GA0.523--0.6131.0801.046--1.1162.66E−064.845,123LOC100507431The table shows all SNPs with *P* \< 5.0E−06

Results {#Sec8}
=======

Meta-analyses of refractive astigmatism GWAS results were carried out for three subject groups: White Europeans aged ≥25 years, White European subjects aged \<25 years, and Asians aged ≥25 years. There was little evidence of population stratification in any of the meta-analysis results (Genomic Control lambda, *λ*~GC~ = 1.014, 1.011, 1.018 and 1.022 for White Europeans aged ≥25 years, White European subjects aged \<25 years, Asians aged ≥25 years, and all samples combined, respectively).

Meta-analysis of White Europeans aged at least 25 years {#Sec9}
-------------------------------------------------------

For the meta-analysis of older White European individuals (*N* = 31,968) there were six regions containing markers with *P* values \<5.0E−06, suggestive of association (Table [2](#Tab2){ref-type="table"}; Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}). However, only a single region contained markers that met the *P* value conventionally accepted to declare genome-wide significance (*P* \< 5.0E−08). This was at 2p16.3, downstream of the gene encoding neurexin-1 (*NRXN1*; Fig. [2](#Fig2){ref-type="fig"}a) with the most strongly associated marker being rs1401327. Each copy of the A allele of rs1401327 increased the odds of astigmatism with an OR 1.16 (95 % CI 1.10 to 1.22; *P* = 3.92E−08). The next most strongly associated regions were at 3q23, 4p15, 6p22.3, and 18q12.1 (Table [2](#Tab2){ref-type="table"}). There was little evidence of heterogeneity of effect across cohorts at any of the above loci (*I*^2^ \< 14; Table [2](#Tab2){ref-type="table"}).Fig. 1Results of the meta-analysis of White European subjects aged ≥25 years old. **a** Manhattan plot of log *P* values against genomic position. The *red horizontal line* is the threshold commonly used to for declaring genome-wide significance (*P* = 5.0E−08). The *blue line indicates* *P* = 1.0E−05. Genes adjacent to the association signal are indicated. **b** Quantile--quantile (QQ) plot of observed versus expected distribution of log *P* values. The *red line* shows the distribution expected by chanceFig. 2Regions showing the strongest evidence for association with refractive astigmatism in the meta-analysis of White Europeans aged ≥25 years

Meta-analysis of White Europeans aged less than 25 years {#Sec10}
--------------------------------------------------------

The meta-analysis of younger White European cohorts identified four regions with *P* values below 5.0E−06 (Table [2](#Tab2){ref-type="table"}). However, the much smaller sample size (*N* = 5,640) meant that this meta-analysis had limited statistical power to detect true-positive associations. The most strongly associated SNP was rs1366200 (OR 1.31, 95 % CI 1.17--1.46; *P* = 1.04E−06) within the *AQPEP* gene on chromosome 5q23.1.

Meta-analysis of Asians aged at least 25 years {#Sec11}
----------------------------------------------

In the meta-analysis of Asian cohorts (*N* = 9,295) the most strongly associated marker was rs7534824 (OR 2.30, 95 % CI 1.65 to 3.22; *P* 9.00E−07) within a gene of unknown function, *LOC101928334*, on chromosome 1. This marker had a low allele frequency (MAF = 0.03). Two other regions also contained SNPs with *P* values \<5.0E−06 (Table [2](#Tab2){ref-type="table"}). However, this meta-analysis also had limited statistical power to detect true-positive associations.

Meta-analysis of all cohorts {#Sec12}
----------------------------

To search for evidence to corroborate the initial findings, we carried out a meta-analysis of all independent individuals from the above three cohort groups combined with Asians \<25 years of age from the SCORM study (*N* = 45,931). As shown in Table [3](#Tab3){ref-type="table"}, this revealed little evidence across cohort groups to substantiate the initial findings. The three most strongly associated regions were the *NRXN1* locus, the *TOX* gene locus on chromosome 8q12.1, and the *LINC00340* gene locus at 6p22.3, all of which were amongst the most highly associated regions identified in the meta-analysis of older White European subjects. Association at the *NRXN1* gene locus (rs1401327, OR 1.139, 95 % CI 1.084--1.198, *P* = 2.93E−07) was driven solely by the European cohorts, since the associated SNPs were monomorphic in Asians, and thus uninformative. The most strongly associated marker at the *TOX* gene locus was rs7823467 (OR 1.09, 95 % CI 1.05--1.12; *P* = 3.47E−07) while that at the *LINC00340* gene locus was rs12212674 (OR 1.09, 95 % CI 1.05--1.12; *P* = 1.49E−06).

Interestingly, the *TOX* region is one of the loci identified in the CREAM consortium GWAS for spherical equivalent refractive error (Verhoeven et al. [@CR84]) and the age of onset of myopia GWAS carried out by 23andMe (Kiefer et al. [@CR44]). Therefore, to investigate whether spherical refraction and astigmatism share common genetic determinants more widely, we examined the association with refractive astigmatism of 34 genome-wide significant SNPs (Table S1) reported in the CREAM (Verhoeven et al. [@CR84]) and 23andMe (Kiefer et al. [@CR44]) spherical equivalent GWAS meta-analyses (4 additional SNPs associated with spherical equivalent could not be included since they were not analysed in the current study). For each SNP, the effect size (beta coefficient describing the magnitude of association) with spherical equivalent was plotted against the effect size for association with refractive astigmatism (Fig. [3](#Fig3){ref-type="fig"}). The betas were found to be highly correlated (*r* = −0.59, *P* = 2.10E−04). Excluding the SNP in the *TOX* gene region had minimal influence on the correlation of the betas for the remaining 33 SNPs (*r* = −0.60, *P* = 2.29E−04).Fig. 3Common genetic determinants for spherical equivalent refractive error are shared with refractive astigmatism. GWAS meta-analysis beta coefficients (which quantify the effect size of SNPs) were compared between studies of spherical equivalent and refractive astigmatism. The SNP beta coefficients for spherical equivalent were obtained from the CREAM consortium GWAS for spherical equivalent (Verhoeven et al. [@CR84]), while those for refractive astigmatism were from the current study. The 34 SNPs analysed were chosen based on prior genome-wide significant evidence of association with spherical equivalent in the CREAM (Verhoeven et al. [@CR84]) and 23andMe (Kiefer et al. [@CR44]) GWAS meta-analyses. The *solid line* is the best linear fit to the data

Discussion {#Sec13}
==========

This GWAS meta-analysis of nearly 46,000 individuals identified several novel, suggestive candidate genes/regions for refractive astigmatism, including *NRXN1*, *TOX* and *LINC00340*. One of these regions, near the *NRXN1* gene region, reached genome-wide significance in the White European adult group. Two-thirds of the \~46,000 subjects included in the full meta-analysis were White European adults and so the results are likely to have been driven mainly by this group. Therefore, until the opportunity arises for replication in independent samples, especially in large numbers of comparable White European adults, caution is needed in interpreting these results. These results should not be considered to be relevant to other populations until replicated in younger White European samples or in other ethnic groups.

Novel candidate genes underlying the observed associations {#Sec14}
----------------------------------------------------------

Neurexin-1, one of the largest genes in the human genome, is thought to function in cell adhesion, as well as synapse development and maintenance (Kirov et al. [@CR45], [@CR46]). Structural genomic deletions that delete or disrupt *NXRN1* are strongly implicated in causing psychiatric and cognitive phenotypes including schizophrenia, autism and mental retardation (Bena et al. [@CR5]). To our knowledge, these conditions are not known to be associated with refractive astigmatism (although refractive errors, in general, are more prevalent in individuals with learning difficulties, Woodhouse et al. [@CR93]). A recent survey of 25 patients with exonic deletions involving the gene for neurexin-1 (Bena et al. [@CR5]) unfortunately did not describe these patients' ocular features. While the strength of association reached genome-wide significance in the adult European sample (*N* = 31,968, *P* = 3.92E−08), this weakened when the younger European subjects were included (*N* = 35,719, *P* = 2.93E−07) while having little impact on the estimated effect size (OR 1.16 and 1.14, respectively). The associated SNPs in this region were monomorphic in Asian subjects, suggesting they arose relatively recently in human evolution.

The associated variants at 8q12.1 lie upstream of the *TOX* promoter and thus would be well placed to influence its transcription level. However, it is not clear whether *TOX* or a nearby gene mediates this locus' impact on spherical equivalent refractive error, and potentially astigmatism. The known roles of *TOX* relate to immune function, which argues against a role in refractive development and instead suggests that another gene such as *SDCBP* (syndecan-binding protein) also known as syntenin, which lies 600 kb from the most strongly associated marker may be involved. Syntenin acts as a link between the proteoglycan/matrix receptor syndecan-1 and the cytoskeleton, and its proposed functions include cell adhesion. Furthermore, syntenin-null mice show wound healing defects that are particularly marked in the cornea (Stepp et al. [@CR80], [@CR81]).

The 6p22.3 locus containing the long intergenic non-coding RNA gene *LINC00340* (also known as *FLJ22536* and *CASC15*) is gene poor (Fig. [2](#Fig2){ref-type="fig"}d) yet has previously shown association with aggressive neuroblastoma in GWAS studies (Capasso et al. [@CR8]). The mechanisms through which non-coding RNAs act are poorly understood (Guttman et al. [@CR28]; Gibb et al. [@CR24]) but in the case of lincRNAs the mechanism may involve epigenetic regulation (Salta and De Strooper [@CR73]). No obvious candidate astigmatism susceptibility gene is present in this genomic location. As with *NRXN1*, the association with *LINC00340* was almost wholly driven by the adult European cohorts (*P* = 1.45E−06 versus *P* = 1.49E−06 in all cohorts combined).

As well as *NRXN1* and *SDCBP*, additional genes in the most strongly associated regions have putative roles in cell adhesion and/or synapse function. The gene nearest to the lead SNP at 3q23 in European adults (rs12638075, *P* = 4.69E−06) is *TRIM42* (tripartite motif containing-42). Because members of the *TRIM* gene family function mostly in immune signalling (Versteeg Gijs et al. [@CR85]), the adjacent gene *CLSTN2* (calsyntenin-2; also known as cadherin-related family member-13) is potentially of greater interest given its proposed role in cell adhesion and synapse function (Preuschhof et al. [@CR68]). Furthermore, the association described above for markers in the vicinity of the *SDCBP* gene, encoding syntenin, lends support to the putative involvement of *CLSTN2*. One of the two regions on chromosome 4p15 (lead SNP rs2871434; Fig. [2](#Fig2){ref-type="fig"}e) contains the *PCDH7* (protocadherin-7) gene, which given its role in cell adhesion is a plausible candidate gene for astigmatism. In mice homozygous for a null allele of the *EGR1* gene, which develop a transient axial myopia postnatally, a member of the protocadherin gene family, *Pcdhb9*, was the most highly differentially expressed retinal gene when compared to wild-type mice (Schippert et al. [@CR74]). The second associated region at 4p15 (lead SNP rs2309717; Fig. [2](#Fig2){ref-type="fig"}b) contains no known genes, the closest being *MIR4275*, which lies 600 kb away. However, amongst the more than 6,000 predicted targets of miR-4275 is the nearby *PCDH7*.

Genetic co-determination of spherical equivalent and refractive astigmatism {#Sec15}
---------------------------------------------------------------------------

One of the most exciting findings from this study was the evidence for overlap in genetic susceptibility between spherical and astigmatic refractive errors (Fig. [3](#Fig3){ref-type="fig"}). It is well known that spherical and astigmatic refractive errors tend to co-occur (Read et al. [@CR72]; Guggenheim and Farbrother [@CR26]). However, to our knowledge this is the first study to provide evidence supporting shared genetic susceptibility for the two traits. Kee and Deng ([@CR39]) and Kee et al. ([@CR40]) have shown in monkeys and chickens that visual experience can alter spherical equivalent and astigmatic refractive errors concurrently. Hence, in line with the view that genetic factors might alter refractive development by regulating how the eye responds to visual cues (Chen et al. [@CR10]; Wallman [@CR88]), it is feasible that causal variants tagged by the SNPs examined here impact on both spherical equivalent and astigmatism via visual feedback.

The suggestive findings here that genes related to cell adhesion and synapse function may be involved in susceptibility to astigmatism is also consistent with the concept of genetic co-determination of spherical equivalent and refractive astigmatism, as several candidate genes identified in GWAS for spherical equivalent refractive error have putative roles in synapse function or plasticity, for example *RASGRF1*, *GRIA4*, *RBFOX1*, *LRRC4C*, *DLG2* (Kiefer et al. [@CR44]; Verhoeven et al. [@CR84]; Stambolian et al. [@CR79]; Hysi et al. [@CR35]) as well as in cell adhesion, for example *TJP2*, *CTNND2*, *ANTXR2*, and *LRFN5* (Kiefer et al. [@CR44]; Li et al. [@CR50]; Verhoeven et al. [@CR84]).

Comparison with previous work and limitations of the current study {#Sec16}
------------------------------------------------------------------

Results from the meta-analysis of all cohorts for SNPs previously associated with astigmatism are shown in Table [4](#Tab4){ref-type="table"}. Because the cohorts studied here overlap substantially with those examined previously (Fan et al. [@CR19]; Lopes et al. [@CR51]), low *P* values were expected---but not found. Thus the *P* values in Table [4](#Tab4){ref-type="table"} provide little evidence for replication of the previously associated markers. This is especially surprising for the corneal astigmatism-associated SNP at the *PDGFRA* locus (Fan et al. [@CR19]), since this has already been replicated in a cohort of differing ethnicity (Guggenheim et al. [@CR27]). Instead, the lack of replication may reflect the different traits examined (corneal versus refractive astigmatism). The other SNPs previously associated with astigmatism did not reach genome-wide significance in the original study, and were associated with astigmatism when analysed as a quantitative trait, which may explain the lack of independent replication.Table 4Results from the meta--analysis of all cohorts for SNPs previously associated with corneal astigmatism (CA) or refractive astigmatism (RA)TraitSNPChrRANRARAF (min--max)OR95 % CI*P* value*I* ^2^*N*GeneReferencesRArs37713952AG0.06--0.301.041.00--1.095.17E−0219.245,324*VAX2*Lopes et al. ([@CR51])CArs76777514TC0.07--0.261.030.99--1.081.03E−0117.945,287*PDGFRA*Fan et al. ([@CR19])RArs7955445CA0.64--0.921.051.01--1.092.01E−02045,245*DNAH5*Lopes et al. ([@CR51])RArs10226930^a^*SHH*Lopes et al. ([@CR51])RArs48584211CT0.33--0.771.051.01--1.081.21E−0210.245,137*MAML2*Lopes et al. ([@CR51])RArs1244512616AG0.02--0.141.020.97--1.094.16E−0121.145,198*XYLT1*Lopes et al. ([@CR51])RArs1164498816GA0.73--0.991.040.98--1.112.46E−01040,369*FOXF1*Lopes et al. ([@CR51])^a^SNP not present in current meta-analysis

Genetic studies of astigmatism are hampered by the variation in its magnitude and orientation with age, and its non-Gaussian frequency distribution, all of which complicate the choice of analysis model. In younger individuals, astigmatism is typically "with the rule" (WTR; axis of minus power cylindrical correcting lens close to horizontal) while in later life it usually switches to "against the rule" (ATR; correcting negative cylinder axis close to vertical) (Mandel et al. [@CR55]; Guggenheim and Farbrother [@CR26]). Amongst the theories explaining this transition, a loosening of eyelid tension is the most widely supported (Read et al. [@CR72]). If it is the case that ATR and WTR astigmatism have different etiologies, then GWAS investigations should attain maximum statistical power by modelling younger and older subjects separately, modelling ATR and WTR astigmatism separately, or in modelling astigmatism as a vector quantity. However, the age-dependent shift in WTR to ATR largely concerns low-level astigmatism whereas higher levels may be more stable over the life course (Baldwin and Mills [@CR4]; Weale [@CR90]). Thus, the present study adopted a dichotomous case/control classification scheme, and analysed younger and older subjects separately, in an attempt to mitigate the effects of axis changes with age. The dichotomization scheme also allayed concerns regarding the non-normality of the trait, although this would have been at the expense of statistical power.

The use of a dichotomous phenotype definition for our GWAS meta-analysis of astigmatism contrasts with the quantitative trait approach used in previous GWAS meta-analyses by the CREAM consortium for refractive error and axial eye length (Verhoeven et al. [@CR84]; Cheng et al. [@CR12]). It has been shown that binary trait GWAS meta-analysis results are sensitive to unequal numbers of cases and controls in individual cohorts, especially when the sample size is small (Willer et al. [@CR92]). However, we found very similar results when overcoming this potential source of bias using an "effective sample size" rather than actual sample size during meta-analysis (Willer et al. [@CR92]). In addition to the problem of unequal case/control sample sizes, we also observed highly inflated type-I errors during initial meta-analysis trials due to extreme OR estimates for a small number of low MAF markers in certain cohorts, e.g. if the minor allele was present in controls but absent in cases. To circumvent this, we pre-screened each GWAS results file, excluding markers with unfeasibly high OR estimates (OR \< 0.2 or OR \> 5.0).

Out of 7 Asian adult cohorts (total *N* = 9,295), 5 were Chinese cohorts (*N* = 5,132, about 55 % of the total Asian adult sample). Therefore, we cannot generalise our results from the Asian adult group with ease. Importantly, the SNP (rs7534824, in the gene *LOC101928334*) which showed the strongest suggestive association in the Asian group was only polymorphic in the Chinese cohorts (monomorphic in the Indian and Malay cohorts). For the other 3 SNPs reported in Table [2](#Tab2){ref-type="table"}, although they are polymorphic in all three ethnic groups, the association signal was mainly driven by the observed association in the 5 Chinese cohorts.

In summary, this large-scale meta-analysis of GWAS studies for refractive astigmatism identified only a single locus that reached genome-wide significance (2p16.3, near *NRXN1*, in European adults) and there was no evidence for replication of this region in younger European individuals or in non-Europeans. Several putative candidate genes with functions relating to cell adhesion and/or synapse function were present in the next most strongly associated regions. Consistent with earlier work, all of the most strongly associated genetic variants identified had small effects, supporting the polygenic nature of genetic susceptibility to refractive astigmatism in the general population. Fewer candidate risk variants were discovered for refractive astigmatism than were found previously by the CREAM consortium for spherical equivalent refractive error (Verhoeven et al. [@CR84]), despite studying similar subject cohorts. Nevertheless, there was compelling evidence for shared genetic susceptibility for spherical and astigmatic refractive errors, implying that the co-occurrence of these traits is, at least in part, genetically determined.
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